1-6 of 6
Lan Wu
Close
Sort by
Journal Articles

Characterization of Aleta-001, a CAR T Engager Designed to Optimize Responses and Prevent Relapses from CAR-19 Therapy

Paul Rennert, Lihe Su, Lan Wu, Roy Lobb, Christine Ambrose
Journal: Blood
Blood (2021) 138 (Supplement 1): 1713.
https://doi.org/10.1182/blood-2021-153295
Published: 2021
Journal Articles

A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo

Paul Rennert, PhD, Lihe Su, PhD, Fay Dufort, PhD, Alyssa Birt, MS, Tom Sanford, Lan Wu, PhD, Christine Ambrose, PhD, Roy Lobb, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 252.
https://doi.org/10.1182/blood-2019-130654
Published: 2019
Journal Articles

CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies

Paul Rennert, PhD, Christine Ambrose, PhD, Lihe Su, PhD, Fay Dufort, PhD, Lan Wu, PhD, Andreas Hombach, PhD, Hinrich Abken, PhD, Roy Lobb, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4457.
https://doi.org/10.1182/blood.V130.Suppl_1.4457.4457
Published: 2017
Journal Articles

Arsenic Containing Triple-Agent Therapy for Acute Promyelocytic Leukemia-Comparison of Tetra-Arsenic Tetra-Sulfide vs. Arsenic Trioxide in the Long-Term Follow-up at a Single Hospital.

Shu-Lan Wu, MD, Dao-Pei Lu, MD, Yan-Li Zhao, MD, Lan-Qing Liang, MD, Jun-Bao He, MD, Wei Zou, MD, Xin-Hong Fei, MD, Bin Jiang, MD, Fu-Xiang Shan, MD, Ping-Di Yang, MD, Jie Zhao, MD, Chun-Rong Tong, MD
Journal: Blood
Blood (2010) 116 (21): 1081.
https://doi.org/10.1182/blood.V116.21.1081.1081
Published: 2010
Journal Articles

Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma

Bohua Li, Lei Zhao, Huaizu Guo, Chong Wang, Xunming Zhang, Lan Wu, Lin Chen, Qing Tong, Weizhu Qian, Hao Wang, Yajun Guo
Journal: Blood
Blood (2009) 114 (24): 5007–5015.
https://doi.org/10.1182/blood-2009-06-225474
Published: 2009
Includes: Supplemental data
Journal Articles

Tetra-Arsenic Tetra-Sulfide Containing Triple-Agent Regimen as the First Line Therapy for Acute Promyelocytic Leukemia: Expeditiously Consecutive Complete Remission and Improved Disease-Free Survival.

Tong Wu, MD, Jie Zhao, M.D., Bin Jiang, M.D., Shu-Lan Wu, M.D., Ping-Di Yang, M.D., Fu-Xiang Shan, M.D., Chun-Rong Tong, M.D., Dao-Pei Lu, M.D.
Journal: Blood
Blood (2007) 110 (11): 591.
https://doi.org/10.1182/blood.V110.11.591.591
Published: 2007